Cortechs.ai | Deep learning enables 60% accelerated volumetric brain MRI

Deep learning enables 60% accelerated volumetric brain MRI

Deep Learning Enables 60% Accelerated Volumetric Brain MRI While Preserving Quantitative Performance: A Prospective, Multicenter, Multireader Trial

Deep learning reconstruction allows 60% sequence scan-time reduction while maintaining high volumetric quantification accuracy, consistent clinical classification, and what radiologists perceive as superior image quality compared with standard of care. This trial supports the reliability, efficiency, and utility of deep learning-based enhancement for quantitative imaging. Shorter scan times may heighten the use of volumetric quantitative MR imaging in routine clinical settings.

[button]Download[/button]

More Resources

10/15/2025

Sharper Screening, Smarter Biopsies: OnQ Prostate and the Next Step in Imaging

Read to learn how OnQ Prostate goes beyond existing solutions like DynaCAD and redefines biopsy precision

10/14/2025

Cortechs.ai Acquires ZepMed to Expand AI-Powered Neuroimaging Capabilities

This strategic acquisition strengthens Cortechs.ai’s position at the forefront of radiological innovation and expands its suite of best-in-class solutions

10/07/2025

Cortechs.ai Expands Partnership with Strategic Radiology to Advance Imaging Innovation Across Private Practices

Cortechs.ai and Strategic Radiology have now broadened their alliance to include Cortechs.ai’s full suite of imaging solutions.

10/06/2025

Clinical Performance of NeuroQuant: Transforming Brain MRI Analysis

NeuroQuant has consistently demonstrated strong clinical performance across multiple conditions, including Alzheimer’s , epilepsy, TBI, and MS.

10/02/2025

WEBINAR: Navigating Category III CPT Codes for Quantitative Imaging

Leveraging Compatible CPT Codes for NeuroQuant and OnQ Prostate

09/29/2025

The Role of NeuroQuant in Supporting Alzheimer’s Disease Care

NeuroQuant equips clinicians and researchers with data that can support earlier recognition of disease, track progression, and evaluate treatment efficacy.
Scroll to Top